The bladder cancer treatment explained
Bladder cancer treatment has advanced significantly over the years, offering patients a range of options tailored to the stage and grade of their disease. The primary goal of treatment is to eradicate the cancer, prevent recurrence, and preserve bladder function whenever possible. The approach depends on various factors such as the tumor’s size, depth of invasion, and whether it has spread beyond the bladder.
Initially, for non-muscle invasive bladder cancer, which is confined to the inner layers of the bladder, the standard treatment often involves transurethral resection of the bladder tumor (TURBT). During this minimally invasive procedure, a doctor uses a cystoscope—a thin tube with a camera and instruments—to remove visible tumors. Following TURBT, patients typically undergo intravesical therapy, where medications are directly instilled into the bladder to reduce the risk of recurrence. The most common agents used include Bacillus Calmette-Guérin (BCG) and mitomycin C, both of which stimulate the immune system or directly attack remaining cancer cells.
When bladder cancer invades the muscle layer, treatment becomes more aggressive. Muscle-invasive bladder cancer often requires a combination of therapies. Radical cystectomy, the surgical removal of the entire bladder, is considered the gold standard for localized muscle-invasive disease. This procedure usually involves removing nearby lymph nodes and parts of adjacent organs, such as the prostate in men or the uterus and ovaries in women. To maintain continence and quality of life, some patients may opt for urinary diversion procedures, which reroute urine through a stoma or create a new reservoir using intestinal segments.
In certain cases where surgery isn’t suitable or the cancer is advanced, systemic treatments come into play. Chemotherapy is often used before surgery (neoadjuvant) to shrink tumors and improve surgical outcomes or after surgery (adjuvant) to eliminate residual disease. For metastatic bladder cancer, where the disease has spread beyond the bladder, systemic therapies are the mainstay. Chemotherapy regimens, typically involving cisplatin-based combinations, can prolong survival. More recently, immunotherapy drugs such as checkpoint inhibitors have emerged as promising options for patients who do not respond to conventional chemotherapy. These agents help the immune system recognize and attack cancer cells more effectively.
Radiation therapy is another option, particularly for patients unable to undergo surgery or as palliative treatment to relieve symptoms. It can be used alone or in combination with chemotherapy, especially when preserving the bladder is a priority. Nonetheless, bladder preservation protocols, involving a combination of radiation and chemotherapy, may be suitable for select patients aiming to avoid radical surgery.
The choice of treatment depends on multiple factors, including the patient’s overall health, preferences, and specific tumor characteristics. Close follow-up with cystoscopies and imaging is essential after treatment, as bladder cancer has a high recurrence rate. Advances in targeted therapies and immunotherapy continue to improve outcomes, offering hope for more personalized and effective management strategies.
Overall, bladder cancer treatment is a multifaceted process, combining surgery, immunotherapy, chemotherapy, and radiation in a way that maximizes efficacy while striving to maintain quality of life.
